Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer TS ID 11769Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments [ID6226]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab duocarmazine for treating HER2-positive unresectable metastatic breast cancer after 2 or more anti-HER2 treatments or after trastuzumab emtansine [ID6318]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive high-risk early breast cancer TS ID 11910Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Inavolisib with palbociclib and fulvestrant for treating HR+/HER2-, PIK3CA mutated locally advanced or metastatic breast cancer TS ID 11990Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy ID6509Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Artificial intelligence technologies for mammography: early value assessmentStatus:Awaiting developmentProgramme:Health technology evaluationExpected publication date: TBC